Remove 2026 Remove Communication Remove FDA
article thumbnail

FDA Publishes Its Draft Strategy Document on Innovative Manufacturing Technologies

The FDA Law Blog

Schwartz — FDA recently published a Federal Register (FR) Notice [ Docket No. FDA-2024-N-3945 ] announcing the publication of a draft strategy document, for public comment, outlining specific actions FDA plans to take to facilitate the use of innovative manufacturing technologies.

article thumbnail

FDA Hosts Webinar for Stage 1 Requirements under LDT Final Rule

The FDA Law Blog

Instead, we focus here on the few notable statements that provide new or more detailed guidance than FDA has previously offered. Prior to February 2, 2026, FDA also said that it does not intend to enforce complaint requirements under 21 CFR 820.198 for developers that are already in compliance with the complaint requirements under ISO 13485.

FDA 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Less than Meets the Eye: LDT Small Entity Compliance Guide Adds Little Insight

The FDA Law Blog

Unfortunately, the guidance for small entities recently published by FDA is little more than a summary digest of the multi-hundred-page final rule. However, the guidance provides no new information on how FDA expects laboratories to implement these new requirements.

article thumbnail

Is the Listing of REMS Patents in the Orange Book Patently Anticompetitive?

The FDA Law Blog

The TAP Pilot is one of the commitments agreed to between FDA and industry as part of the Medical Device User Fee Amendments of 2022 (MDUFA V) and the Agency hopes the program will help ensure that U.S. Devices in the Safer Technologies Program (STeP) will be included in FY 2026. See Announcement. See Program Website.

article thumbnail

“TAP Dancing” Towards Faster Device Commercialization: CDRH’s Total Product Life Cycle Advisory (“TAP”) Program

The FDA Law Blog

In the ever-changing landscape of medical device development, FDA is touting steps it is taking that it says will enhance efficiency, foster innovation, and address key challenges faced by developers. It remains to be seen how FDA would define and actually implement the role of a TAP Advisor.

FDA 45
article thumbnail

CDRH’s Plan to De-risk the Medical Device Valley of Death

The FDA Law Blog

The TAP Pilot is one of the commitments agreed to between FDA and industry as part of the Medical Device User Fee Amendments of 2022 (MDUFA V) and the Agency hopes the program will help ensure that U.S. Devices in the Safer Technologies Program (STeP) will be included in FY 2026. See Announcement. See Program Website.

article thumbnail

DSCSA Postponement And What It Means For Independent Pharmacies

DiversifyRx

Small Dispensers and the 6/12/2024 FDA Announcement Concerning DSCSA This week’s article on the recent DSCSA postponement comes from PRS Pharmacy Services. The exemption will last until November 27, 2026, for those small dispensers who qualify. We need more clarity here to see what the FDA is planning.